Lithium prophylaxis of recurrent affective disorders.
The mode of action of lithium is reviewed in the light of advances in the understanding of calcium channelling and calmodulin-activated Ca ATPase. The relevance to changes in receptor sensitivity is discussed.
Glen
A I
AI
D000251:Adenosine Triphosphatases / Q000097:blood; D000818:Animals; D001714:Bipolar Disorder / Q000201:enzymology / Q000235:genetics / Q000517:prevention & control*; D002118:Calcium / Q000097:blood; D002135:Calcium-Binding Proteins / Q000097:blood; D002147:Calmodulin / Q000097:blood; D002940:Circadian Rhythm / Q000187:drug effects; D006801:Humans; D007473:Ion Channels / Q000187:drug effects; D008094:Lithium / Q000627:therapeutic use*; D010281:Parathyroid Hormone / Q000097:blood; D017981:Receptors, Neurotransmitter / Q000187:drug effects
D002135:Calcium-Binding Proteins; D002147:Calmodulin; D007473:Ion Channels; D010281:Parathyroid Hormone; D017981:Receptors, Neurotransmitter; D008094:Lithium; D000251:Adenosine Triphosphatases; D002118:Calcium